Xpert® GBS
For direct intrapartum screening in labor/delivery
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
Unit price
Product is not available for purchase in your region.
Collection devices
product image
Collection Device (Pack of 50)
Unit price
Product is not available for purchase in your region.
Error adding items to cart. If this error persists, please contact Digital Support

The Need

In the U.S., Group B Streptococcus (GBS) remains a leading cause of early onset neonatal sepsis. Rates of maternal colonization have not changed, but universal antenatal screening at 35-37 weeks along with the use of intrapartum antibiotic prophylaxis (IAP) has resulted in a decrease of early onset disease.
Challenges remain, including:
  • Risk-based IAP exposes 65-85% of GBS-negative women with risk factors to antibiotics. This has been linked to emergence of resistant strains3
  • Up to 50% false negatives when testing with agar alone4
(1) CDC. (2010). Prevention of Perinatal Group B Streptococcal Disease, Revised Guidelines. Morbidity and Mortality Weekly Report, Vol.59.
(2) ACOG, A.C. (2011). Prevention of Early-Onset Group B Streptococcal Disease in Newborns. Committee Opinion, 1.
(3) Alfa, M. J. (Sept. 2010). Real-Time PCR Assay provides reliable assessment of intrapartum carriage of group B streptococcus. Journal of Clinical Microbiology, 3095-3099.
(4) Paolucci, M. E. (2012). How can the microbiologist help in diagnosing neonatal sepsis? International Journal of Pediatrics, 14.

The Solution

Cepheid's Xpert® GBS test is the only in vitro diagnostic test to fully meet CDC criteria for rapid intrapartum GBS testing. With results in less than an hour, Xpert GBS delivers 91.9% sensitivity and 95.6% specificity.
Not just a solution, a complete solution - Cepheid's GeneXpert System, with Xpert® GBS LB and Xpert GBS is the only solution able to fully meet CDC criteria for both antenatal and intrapartum testing.
On-demand molecular testing — an ideal solution:
  • System designed with Early Assay Termination (EAT) with positive samples reported STAT
    • As soon as positive sample is confirmed, software concludes test and reports immediately.
  • Moderately complex testing with
    • STAT intrapartum specimens can be performed by lab, or by labor and delivery staff
    • Random access ensures any test on the menu can be run anytime, without the need to batch

The Impact

Xpert GBS is the first and only molecular test designed to be run in the clinical lab and near-patient by non-laboratory professionals such as labor and delivery nurses — 24 hours a day, 365 days a year.